CDK4 and neoplasm: Our analysis suggests that expression/activation of CDK4/6 substrates in tumor cells and genomic-independent activation of the AKT/mTOR pro-survival signaling pathway in tumor and surrounding stroma/immune cells may predict response to CDK4/6 inhibition in combination with ET in MBC.